Possibility radiological methods in diagnostics of visceral adiposity

Obesity is present in over 50% of men and 70% of women. Greater health risks development of cardio-vascular disease have been associated with the visceral obesity. Computed tomography is the reference method for intra-abdominal fat evaluation, but high cost, low availability and ionizing radiation risks prevent it from being a widely usable method. Ultrasound measurement of intra-abdominal distance between abdominal muscle and aorta, which has been shown to correlate well with computed tomography intra-abdominal fat measurements, is proposed together with other anthropometric measurements as an alternative means of predicting body fat and also confirmed as a reliable instrument for clinical and epidemiologic studies.

Download Full-text

A New Approach for Cardio Vascular Disease Prediction Using Decision Tree

International Journal of Psychosocial Rehabilitation ◽

10.37200/ijpr/v24i5/pr2020796 ◽

2020 ◽

Vol 24 (5) ◽

pp. 7944-7952

Author(s):

Dr. Saravanabhavan C.

Keyword(s):

Decision Tree ◽

Vascular Disease ◽

Disease Prediction ◽

New Approach ◽

Cardio Vascular Disease ◽

Cardio Vascular

Download Full-text

Hyper-Coagulable Profile with Elevated Pro-Thrombotic Biomarkers and Increased Cerebro- and Cardio-Vascular Disease Risk Exist Among Healthy Dyslipidemic Women

Current Neurovascular Research ◽

10.2174/1567202611666140307104724 ◽

2014 ◽

Vol 11 (2) ◽

pp. 142-148 ◽

Cited By ~ 1

Author(s):

Claudia Ferreira ◽

Maria Carvalho ◽

Helton Reis ◽

Karina Gomes ◽

Marinez Sousa ◽

...

Keyword(s):

Vascular Disease ◽

Disease Risk ◽

Cardio Vascular Disease ◽

Cardio Vascular

Download Full-text

Rebalance the oral microbiota as efficacy tool in endocrine, metabolic, and immune disorders

Endocrine Metabolic & Immune Disorders - Drug Targets ◽

10.2174/1871530320666200729142504 ◽

2020 ◽

Vol 20 ◽

Cited By ~ 5

Author(s):

Ciro Gargiulo Isacco ◽

Andrea Ballini ◽

Danila De Vito ◽

Kieu Cao Diem Nguyen ◽

Stefania Cantore ◽

...

Keyword(s):

Systemic Disease ◽

Current Treatment ◽

Oral Bacteria ◽

The Body ◽

Oral Microbiota ◽

Oral Diseases ◽

Philosophical Approach ◽

Treatment And Prevention ◽

Cardio Vascular Disease ◽

Cardio Vascular

: The current treatment and prevention of oral disorders follow a very sectoral control and procedures considering mouth and its structures as system completely independent from the rest of the body. The main therapeutic approach is carried out on just to keep the levels of oral bacteria and hygiene in an acceptable range compatible with one-way vision of oral-mouth health completely separated from a systemic microbial homeostasis (eubiosis vs dysbiosis). This can negatively impact on the diagnosis of more complex systemic disease and its progression. Dysbiosis is consequence of oral and gut microbiota unbalance with consequences, as reported in current literature, in cardio vascular disease, diabetes mellitus, rheumatoid arthritis, and Alzheimer’s disease. Likewise, there is the need to highlight and develop a novel philosophical approach in the treatments for oral diseases that will necessarily involve non-conventional approaches.

Download Full-text

AN X‐RAY STUDY OF CARDIO‐VASCULAR DISEASE

The Medical Journal of Australia ◽

10.5694/j.1326-5377.1944.tb51639.x ◽

1944 ◽

Vol 1 (7) ◽

pp. 130-130

Keyword(s):

Vascular Disease ◽

X Ray ◽

Cardio Vascular Disease ◽

Cardio Vascular

Download Full-text

Associations between smoking and blood-group, and the risk of dyslipidaemia amongst French women

Scientific Reports ◽

10.1038/s41598-021-94239-9 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

C. J. MacDonald ◽

A. L. Madika ◽

G. Severi ◽

A. Fournier ◽

M. C. Boutron-Ruault

Keyword(s):

Blood Group ◽

Smoking Status ◽

Effect Modification ◽

Blood Groups ◽

Cross Sectional ◽

Increased Risk ◽

Cardio Vascular Disease ◽

Never Smokers ◽

Cardio Vascular ◽

Incident Cases

AbstractDyslipidaemia is a major risk factor for cardio-vascular disease, as it promotes atherosclerosis. While cross-sectional studies have identified higher serum cholesterol amongst individuals with the A blood group, there is less evidence from prospective studies whether this translates into a higher risk of dyslipidaemia that requires treatment, nor if this genetic factor interacts with smoking status. This study aimed to prospectively determine potential associations between smoking, ABO blood groups, and risk of incident dyslipidaemia requiring treatment, and to assess associations over strata of blood ABO group. We assessed associations between blood ABO group, smoking and dyslipidaemia in 74,206 women participating in the E3N cohort. We included women who did not have cardiovascular disease at baseline. Logistic regression was used to determine associations between ABO group, smoking and prevalent dyslipidaemia at baseline. Cox proportional hazard models were then used to determine if blood ABO group and smoking were associated with the risk of incident dyslipidaemia, amongst women free of dyslipidaemia at baseline. At baseline 28,281 women with prevalent dyslipidaemia were identified. Compared to the O-blood group, the non-O blood group was associated higher odds of with prevalent dyslipidaemia (ORnon-O = 1.09 [1.06: 1.13]). Amongst the women free of dyslipidaemia at baseline, 6041 incident cases of treated dyslipidaemia were identified during 454,951 person-years of follow-up. The non-O blood groups were associated with an increased risk of dyslipidaemia when compared to the O-group (HRnon-O = 1.16 [1.11: 1.22]), specifically the A blood-group (HRA = 1.18 [1.12: 1.25]). Current smokers were associated with an increased risk of incident dyslipidaemia (HR smokers = 1.27 [1.16: 1.37]), compared to never-smokers. No evidence for effect modification between smoking and ABO blood group was observed (p-effect modification = 0.45), although the highest risk was observed among AB blood group women who smoked (HR = 1.76 [1.22: 2.55]). In conclusion, the non-O blood groups, specifically the A group were associated with an increased risk of dyslipidaemia. Current smokers were associated with a 30% increased risk of dyslipidaemia. These results could aid in personalised approaches to the prevention of cardiovascular risk-factors.

Download Full-text

Hepatic steatosis in Cushing's syndrome: a radiological assessment using computed tomography

Acta Endocrinologica ◽

10.1530/eje.0.1490543 ◽

2003 ◽

Vol 149 (6) ◽

pp. 543-548 ◽

Cited By ~ 91

Author(s):

AG Rockall ◽

SA Sohaib ◽

D Evans ◽

G Kaltsas ◽

AM Isidori ◽

...

Keyword(s):

Computed Tomography ◽

Hepatic Steatosis ◽

Cushing’S Syndrome ◽

Negative Correlation ◽

Visceral Fat ◽

Subcutaneous Fat ◽

Significant Negative Correlation ◽

Cushing's Syndrome ◽

Abdominal Fat ◽

Visceral Fat Area

OBJECTIVE: Hepatic steatosis may occur in association with insulin resistance and obesity, two features commonly seen in Cushing's syndrome (CS). The aim of this report is to assess the prevalence of hepatic steatosis in patients with active CS using computed tomography (CT) and to identify any associations between hepatic steatosis, endocrine and biochemical variables and body fat distribution. PATIENTS AND MEASUREMENTS: We identified 50 patients with active CS in whom appropriate CT was available to allow measurement of liver and spleen attenuation. In 26 patients, abdominal fat measurements were also available. Serum markers of CS and liver function tests were recorded. RESULTS: Ten of 50 patients had a liver-to-spleen CT attenuation ratio (L/S) of less than 1, indicating hepatic steatosis. There was a significant negative correlation between both liver attenuation and L/S ratio with total abdominal fat area, visceral fat area, the percentage of visceral fat and the visceral to subcutaneous fat ratio; the strongest negative correlation was found between visceral fat area and L/S ratio (r=-0.638, P<0.001, n=26). L/S ratio positively correlated with alkaline phosphatase levels (r=+0.423, P=0.044, n=23) but with no other serum marker of CS activity or liver enzyme. CONCLUSIONS: We have demonstrated hepatic steatosis on CT in 20% of patients with active CS. The presence of hepatic steatosis was significantly correlated with total abdominal fat area and visceral fat area.

Download Full-text

The Effect of Fasting Month of Ramadan on the Abdominal Fat Distribution: Assessment by Computed Tomography

The Tohoku Journal of Experimental Medicine ◽

10.1620/tjem.204.179 ◽

2004 ◽

Vol 204 (3) ◽

pp. 179-187 ◽

Cited By ~ 41

Author(s):

Aylin Yucel ◽

Bumin Degirmenci ◽

Murat Acar ◽

Ramazan Albayrak ◽

Alpay Haktanir

Keyword(s):

Computed Tomography ◽

Fat Distribution ◽

Abdominal Fat

Download Full-text

Abdominal Laser Lipolysis Using a Microprocessor-Controlled Robotic Arm with Non-Contact Heating and Cooling

Aesthetic Surgery Journal ◽

10.1093/asj/sjab206 ◽

2021 ◽

Author(s):

Thomas Fiala

Keyword(s):

Cooling System ◽

Subcutaneous Fat ◽

Treatment Protocol ◽

Abdominal Fat ◽

Abdominal Circumference ◽

Ordinal Scale ◽

Robotic Arm ◽

Ultrasound Measurement ◽

Fat Thickness ◽

The Mean

Abstract Background A novel FDA-cleared device uses a 1064 nm laser to non-invasively induce apoptosis for lipolysis of subcutaneous abdominal fat while maintaining comfortable skin temperatures with a proprietary jet cooling system (eon ®, Dominion Aesthetic Technologies, Inc.; San Antonio, TX). A programmable articulated robotic arm moves the treatment head without any subject contact, maintaining an appropriate three-dimensional treatment path, compensating for patient movement. Objectives The goal of this prospective, single center, open-label study was to demonstrate the safety and effectiveness of this device for reducing subcutaneous abdominal fat using an updated power delivery curve. Methods Male and female subjects with Fitzpatrick skin types I-VI (N=26) were treated. Four abdominal zones up to 150 cm 2 each, customized in size and location for body habitus were treated. Each zone underwent a single 20-minute treatment session. Follow-up visits occurred after 6 and 12 weeks. Using a standardized protocol, ultrasound measurement of subcutaneous abdominal fat thickness, abdominal circumference, reported patient satisfaction and digital images were obtained. Results The mean treatment area was 378.5 cm 2. At Week 12, there was a 21.6% mean reduction in abdominal subcutaneous fat thickness and a 4.1-cm (1.6-inch) mean reduction in abdominal circumference. Most subjects (84.6%) were satisfied or very satisfied with their results. The mean pain score was 2.5 on an 11-point ordinal scale. There were no non-responders. Only two adverse events were noted: mild transient erythema (n=1, 3.8%) and localized subcutaneous firmness (n=1, 3.8%) which resolved without intervention within 12 weeks. Conclusions This contact-free device is safe and effective for reducing subcutaneous abdominal fat and represents an improvement on the prior treatment protocol.

Download Full-text